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SUMMARY
Nausea and vomiting seen within the post-operative recovery room or 24 hours following the opera-
tion remain one of the most common complications in the postoperative period. Nausea and vomiting 
decrease the patient's postoperative satisfaction, which may lead to complications, such as aspiration 
of gastric contents, dehydration, electrolyte imbalance, hemorrhage, it may also bring about economic 
losses, prolongs recovery time and length of hospital stay. Therefore, in the preoperative process, it is 
very important to investigate the risks correctly for each patient concerning postoperative nausea and 
vomiting and to identify and apply risk-reducing pharmacological and non-pharmacological treatment 
methods. In this review, the importance of postoperative nausea and vomiting, risk factors, strategies to 
reduce risks and the treatment algorithm used in prophylaxis are presented.
Keywords: Postoperative nausea-vomiting; postoperative nausea-vomiting risk factors; postoperative nausea-vom-
iting prevention; postoperative nausea-vomiting treatment algorithm.




Postoperative nausea and vomiting (PONV) is an is-
sue that has achieved high attention in the 1990s and 
never lost its popularity concerning anesthesia. Briefly, 
PONV is the feeling of nausea, vomiting and retching 
within 24 hours after the operation or in the recovery 
room.
Significance of PONV
A study about the importance of PONV, patients were 
asked to write 10 outcomes, starting with the most un-
wanted outcome in the postoperative period. At the 
end of the study, vomiting was taken the first order, and 
incision pain was the third. In other words, vomiting 
was the most undesirable complication and was even 
more important than incisional pain for patients.[1] 
In another study, patients were asked how much they 
would pay for an antiemetic if it were guaranteed that 
they would not have PONV experience. The patients 
agreed to pay an average of $56(26-97). In the same 
study, when the patients were asked how much they 
would pay to avoid PONV, they agreed to pay $73(44-
110).[2] In another study, families whose children had 
surgery in the last two years were selected, and their 
parents were asked how much they would pay to pre-
vent their children from having PONV. The families 
agreed to pay around $80. The families also mentioned 
that they were very worried about PONV.[3] In a study 
on the cost of PONV, it was mentioned that each vom-
iting attack caused the patient to leave the recovery 
room 24 minutes later. In addition, the total cost of 
staff, support equipment, medication for each patient 
with a PONV attack was approximately $15.[4] As a 
result, the importance of PONV is:
• A serious stress factor for patients and parents
• Cause of morbidity
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opioids posed a weak risk and no difference between 
opioid types.[8]
Children
Unlike adults in children, all data were collected on 
vomiting in the literature because it is not quite pos-
sible to evaluate nausea objectively. PONV is not fre-
quently seen in children under the age of two. In chil-
dren over three years of age, the incidence of vomiting 
is twice that of adults and around 40%. When the three 
consecutive guidelines are considered concerning risk 
factors, a big difference is not seen in children.
Simplified Risk Scores for Predicting PONV
In 1999, Apfel et al. determined simplified risk scoring 
for adults. According to this scoring, there are four in-
dependent predictors as follows: 
• Female gender
• Non-smoking status
• History of nausea-vomiting or motion sickness
• Postoperative opioid consumption 
The risk factors are summed and an estimated 
PONV percentage is determined. For instance, if there 
is 0, 1, 2, 3,4 risk factors, PONV risk respectively about 
10%, 20%, 40%, 60% and 80%.[5]
Similar to the adult PONV scoring, Eberhart et al. 
have defined a simple risk score for PONV purposes 
in pediatrics. There are four independent predictors in 
this scoring system:
• Duration of surgery ≥30 minutes
• Age ≥3
• Strabismus surgery
• History of postoperative vomiting in the patient, 
the parents of the patient and the twin of the pa-
tient
In the same manner, the risk factors are summed 
and a postoperative vomiting (POV) percentage is de-
termined. For instance, if there is 0, 1, 2, 3, 4 risk fac-
tors, the risk of POV 10%, 10%, 30%, 50% and 70%.
[9]
Due to the increasing number of outpatient surgeries 
nowadays, a nausea-vomiting scoring was created for 
the post-discharge period. Five independent predictors 
were determined in this scoring system as follows:
• Female gender
• PONV history 
• Being under the age of 50
• Use of opioids in the recovery room
• Nausea in the recovery room
According to this scoring system, if there is 0, 1, 2, 
3, 4, 5 risk factors, the risk of post-discharge nausea 
and vomiting (PDNV) 10%, 20%, 30%, 50%, 60% and 
89%.[10]
(Aspiration, suture opening, esophageal rupture, 
electrolyte imbalance, dehydration)
• Prolongation of recovery
• Cause of admission to the hospital 
When all these results are considered, it is seen that 
PONV increases hospital costs significantly.
Incidence of PONV
There are serious complications that are very impor-
tant in anesthesia practice but have a low incidence. 
Malignant hyperthermia is a good example. It is very 
important when it occurs; however, its incidence is 
around 1/15000, whereas PONV is both important 
and its incidence is high. In the postoperative stage, 
the general vomiting incidence is 30%, general nau-
sea incidence is 50%. Moreover, PONV incidence in-




Upon the rise of interest in PONV and the increase in 
the publications, it has been decided to bring experts 
throughout the world and to publish a guideline in 
2003. It was reported that giving prophylaxis to each 
patient against the risk of PONV increases the costs 
and exposed patients to the side effects of the medica-
tions. It was mentioned that prophylaxis should only 
be administered to patients with medium and high risk 
for this reason.[6]
The risk factors related to PONV were published 
in the 2003, 2007 and 2014 guidelines with certain 
differences. The risk factors specific to patients in the 
2003 guideline were belonging to the female gender, 
non-smoking status and the history of PONV or mo-
tion sickness. The modifiable or anesthesia-related 
risk factors are the use of volatile anesthetics, nitrous 
oxide, intraoperative and postoperative opioids. As 
for surgical risk factors, the duration of surgery is im-
portant. Each 30-minute extension in the duration of 
surgery increases basal risk around 60%. In addition, 
surgical types are also important (laparoscopy, ear-
nose-throat, neurosurgery, breast, strabismus, laparo-
tomy, plastic surgery).[6] There is no much difference 
between the 2003 and 2007 guidelines, only the type 
of operation has been increased (laparoscopy, laparo-
tomy, breast, strabismus, plastic surgery, maxillofa-
cial, gynecological, abdominal, neurologic, ophthal-
mologic, urologic).[7] In the guideline of 2014, being 
under the age of 50 was exactly added as a risk factor. 
When all surgery groups were analyzed, cholecystec-
tomy, gynecological and laparoscopic surgeries car-
ried more risk. It was emphasized that intraoperative 
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The Strategies which Reduce Basal Risks
In the prevention of PONV, pharmacological treat-
ments are not sufficient enough. Therefore, strategies 
that reduce basal risks were included in all three of 
the guidelines. In the 2003 guideline, it was stated 
that regional anesthesia reduces PONV 11 times 
compared to general anesthesia. It was reported that 
the use of propofol in induction and maintenance 
reduces PONV in an effective manner in particular 
in the first six hours. Although it was changed in the 
other two guidelines, perioperative support oxygen 
(80%) reduces PONV by 50%. While hydration re-
duces PONV, nitrous oxide, volatile anesthetics, in-
traoperative/postoperative opioids and high dosage 
neostigmine (≥2.5mg) increases PONV. Similar to 
multimodal analgesia, a multimodal approach is su-
perior to monotherapy in the prevention of PONV.
[6] The support oxygen treatment found in the 2003 
guideline did not exist in the 2007 guideline. The re-
ducing effect of propofol was indicated in the 2007 
guideline as well. Meanwhile, two published meta-an-
alyzes indicate that the absence of nitrous oxide re-
duces PONV. It was reported that volatile anesthetics 
increased PONV, especially in the first two hours and 
not effective in the remaining 22 hours. In addition, 
non-opioid analgesics and ketamine reduce PONV 
through a mechanism to reduce opioid use.[7]
In 2004, a publication in NEJM (IMPACT) pre-
sented important findings of the issue. Five thousand 
one hundred ninety-nine patients were applied to six 
different treatment strategies. In patients who used 
volatile anesthetics or nitrous oxide, the PONV inci-
dence was indicated as 59%. It was determined that 
the use of propofol reduces the risk of PONV by 19%, 
non-use of nitrous oxide by 12% and application of to-
tal intravenous anesthesia (TIVA) by 25%. In the same 
study, it is stated that the use of ondansetron 4mg, 
droperidol 1.25 mg and dexamethasone 4mg in the 
treatment are equally effective and that each reduces 
the risk of PONV by 25%.[11]
In the 2014 guideline, different from 2007, sup-
portive O2 therapy and minimization of neostig-
mine use are not included in the strategies to reduce 
baseline risks. In addition to postoperative opioids, 
the minimization of intraoperative opioids was also 
added.[8] After postoperative nausea and vomiting 
risk assessment, prophylaxis algorithm can be per-
formed (Fig. 1).
General Strategies to Prevent Postoperative Nausea-
vomiting
1. Determine the PONV risk of the patient (low, 
medium, high)
2. Plan an antiemetic with the purpose of prophylaxis
Fig. 1. Postoperative nausea and vomiting (PONV) prophylaxis algorithm.
PONV risk evaluation
No need for prophylaxis
Except for special cases where complications 
may occur due to vomiting
Think about regional anesthesia.
Avoid n2O and volatile anesthesia.
Use minimal intraop and postop opioids
Apply TIVA
Apply sufficient hydration
2-3 different prophylactic antiemetics 
from different groups
Monotherapy (adult)
Combination therapy (adult or pediatric)
Medium and high risk
Medium and high risk High risk group
Low risk
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 (e.g., Put a scopolamine patch two hours before 
min induction)
3. If PONV develops, calculate the possible problems
 (e.g., Opening of a wound, increase in the intracra-
nial pressure, aspiration due to jaw braces)
4. The anesthesia technique should be modified
 (e.g., TIVA instead of sevoflurane anesthesia and 
regional anesthesia instead of general anesthesia)
5. Postoperative pain control (multimodal analgesia)
 (e.g., Acetaminophen, local anesthetic application, 
regional anesthesia/analgesia, wound site infiltra-
tion)
6. Antiemetic planning for the rescue purposes 
 Choose a different group antiemetic from the group 
which was planned for prophylaxis
 (e.g., Ondansetron in prophylaxis, prochlorper-
azine, droperidol in saving)
7. Optimal hydration should be provided
(There is no difference between fluid types)
Approach Strategies according to Risk Groups
A. Approach for the adult patient with high risk
Multimodal approach (Apfel PONV risk score 4): 
Triple approach
1. Anesthesia technique: Regional anesthesia if possi-
ble; if general anesthesia is necessary, then, TIVA as 
a choice
2. Antiemetics: From different groups
 Scopolamine patch: two hours before minimum in-
duction
 Dexamethasone 4mg iv before induction
 Ondansetron 4mg iv at the end of the surgery
3. Postoperative Pain Control: Acetaminophen, re-
gional blocks, wound site infiltration 
B. Approach for the adult patient with medium risk
(Apfel PONV risk score 2-3): Dual approach
1. Anesthesia technique: If possible regional, TIVA if 
general anesthesia is necessary
2. Antiemetics:
Dexamethasone 4mg iv before induction or
Ondansetron 4mg iv at the end of the surgery
C. Approach for pediatric patients with high risk
Multimodal approach (Eberhart PONV risk score 
3-4): 
1. Anesthesia technique: If possible regional anesthe-
sia+ sedation, 
 TIVA if general anesthesia is necessary (if there is a 
very high risk)
2. Antiemetics: 
 Dexamethasone 0.25 mg/kg iv, max 4 mg
 Ondansetron 0.1 mg/kg iv, max 4 mg
3. Postoperative Pain Control: 
Acetaminophen 15 mg/kg iv, 15-30 mg rectal, max 
750 mg
Dexmedetomidine infusion 0.3 mg/kg iv 10 minutes 
Regional blocks, wound site infiltration 
D. Approach for pediatric patients with medium risk
Multimodal approach (Eberhart POK risk score 2): 
1. Anesthesia technique: If possible regional anesthe-
sia+sedation 
2. Antiemetics:
 Dexamethasone 0.25 mg/kg iv, max 4mg
 Ondansetron 0.1 mg/kg iv, max 4mg
3. Postoperative Pain Control: 
Acetaminophen 15 mg/kg iv,15-30 mg rectal, max 
750 mg Dexmedetomidine infusion 0.3 mg/kg iv 10 
minutes,
Regional blocks, wound site infiltration
E. Approach for adults & children with low risk:
Basically in the approach to a low risk patient, 
antiemetic is not required unless PONV occurs.
It can be applied in some specific surgeries (esopha-
gus surgery, surgeries ended with dental braces)
In a study of hydration and PONV, 100 pediatric 
strabismus patients were selected. The children were 
randomized into two groups as Group I (10 ml/kg RL 
iv) and Group II (30 ml/kg RL iv). The incidence of 
PONV (22%) was lower in the high hydration group 
than in the low hydration group (54%). However, when 
the literature was reviewed, the superiority between 
fluid types was not shown.
Pharmacological Treatment in PONV Prophylaxis 
Studies have shown that very different medication 
groups can be used for PONV prophylaxis. The opti-
mal dosages and times of use were clearly indicated. 
Brief information about the primary medication is as 
follows: 
a. 5-HT3 Receptor Antagonists
Ondansetron: The gold standard use in the literature is 
4 mg intravenously. Studies show that 8 mg of oral on-
dansetron has a similar effect. Its effect on vomiting is 
greater than its the effects on nausea. It does not have a 
sedative effect. The suggested optimal time of use is the 
end of the surgery. Its main side effects are headache, 
increased liver enzymes and constipation.
Palonosetron: Palonosetron is the latest serotonin 
receptor, antagonist. Its half-life is long (about 40 
hours). It does not affect the QT interval. It is adminis-
tered when the surgery is about to end. The suggested 
dosage for adults is 0.075 mg and 2.5 mcg intravenous 
for children.
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b. NK-1 Receptor Antagonists
Aprepitant: There are 80 mg and 40 mg oral dosages. 
Studies have shown that 80 mg is the ideal dosage.[12]
Its half-life is about 40 hours. In a study, it was shown 
to be superior to ondansetron 4mg concerning vomit-
ing for 48 hours.[13] In general, it is used for nausea-
vomiting after cancer cases.
Fosaprepitant: It is the parenteral form.
Rolapitant: It is the new long-acting NK-1 antago-
nist. Its effect time is about 72-120 hours. Its oral form 
is 90mg tablets and can be found in the USA since 
2015. Its emulsion form is 166.5mg and can be found 
in the USA since 2017. Due to its long-acting effect, it 
is ideal for ambulatory surgery.
c. Corticosteroids
Dexamethasone: It has a similar effect with ondansetron 
4 mg and droperidol 1.25 mg in prophylaxis.[11] One 
of their superior characteristics is that they reduce opi-
oid consumption due to having postoperative analgesic 
effects. There have been ongoing discussions about cor-
ticosteroids. One of these discussions is about whether 
a single dose increases wound infection or not.[14,15] 
What is certain is that it increases blood sugar for about 
6-12 hours, even with the use of non-diabetics. In this 
respect, the property should be considered when using 
it. It is also troublesome in pediatric oncology patients 
because it may lead to tumor lysis syndrome, as well as 
interact with blood marrow cells.
d. Butyrophenones
Droperidol: 0.625-1.25 mg dosages are used at the end 
of surgery. However, according to FDA, it is in the 
black box list since it extends the QT and can never be 
the first choice in antiemetics treatment.
Haloperidol: It is used in low dosages (0.25-2mg) 
intramuscularly or intravenously. Its primary side ef-
fects are prolonged QT and extrapyramidal symptoms. 
There is no FDA approval for antiemetic and intra-
venous use. It can be used at the beginning or the end 
of surgery because there is no difference in its effect.
e. Antihistamines
Dimenhydrinate/Diphenhydramine: They are as ef-
fective as dexamethasone and droperidol. The adult 
dosage is 1 mg/kg and the child dosage is 0.5 mg/kg 
maximum 25 mg intravenously. Dimenhydrinate is 
used in oral, im and rectal form. One of the uncer-
tainties about this group of drugs is the dose-response 
and the lack of optimal administration time. In this 
group of medication, one of the uncertainties is the 
dosage reaction and optimal time of use. Their pri-
mary side effects are sedation, mouth dryness, dizzi-
ness, urinary retention and agitation caused by uri-
nary retention.
f. Propofol
Propofol is one of the most frequently used medica-
tions in the daily practice of anesthesia. The plasma 
concentration differs depending on the purpose of 
use. The plasma concentration required for general 
anesthesia is about 3-6 mcg/mL and 1-3mcg/mL for 
sedation, whereas it is 343 ng/mL for the emergence 
of antiemetic effect. In a study, it has been shown that 
when propofol is used in induction and maintenance, 
it reduces PONV by 25% in particular in the first six 
hours.[11] In a systematic review in which propofol 
was compared with inhalation anesthetics (sevoflu-
rane, desflurane, isoflurane), it was shown that it re-
duces nausea-vomiting after discharge.[16] What is 
more, it has been shown that when 20 mg propofol, 
which is a very low dosage in daily practice, is used as 
an additional antiemetic, it is as effective as 4mg of on-
dansetron.[17]
g. Metoclopramide
It is a weak antiemetic and its place in PONV prophy-
laxis should be discussed. Although it is effective in 
large dosages, these dosages (25-50 mg) cause side ef-
fects, such as hypotension, tachycardia and extrapyra-
midal symptoms. It is not used in children under the 
age of 1 and it takes the last place in children’s antiemet-
ics preferences (0.1 mg/kg iv, max 10 mg).
Combination Prophylaxis
In PONV prophylaxis, combination treatments are 
superior to a single treatment. When the literature is 
reviewed, the most common drug in combinations 
is ondansetron. In adults, the maximum medication 
dosages to be used in combinations are ondansetron 4 
mg, dexamethasone 8 mg, droperidol 1 mg, haloperi-
dol 1.5 mg and propofol 0.5 mg/kg. Since there is no 
need to use the medication in large dosages in combi-
nation treatments, no side effects have been observed.
If the combination examples in the literature are ana-




PONV Prophylaxis Approach for Pediatric Patients
The medication used for prophylaxis in pediatric 
patients is similar as well (dexamethasone, dimen-
hydrinate, dolasetrone, droperidol, granisetrone, 
ondansetron, tropisetrone). When the combination 
preferences are reviewed in the literature, it is seen 
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that drugs, such as ondansetron+dexamethasone and 
ondansetron+droperidol, tropisetrone+dexametha-
sone, are preferred. Ondansetron is seen as the first 
choice in pediatric patients as well as adults. However, 
there are limitations to the use of ondansetron in chil-
dren. Ondansetron’s use in children below the age of 
four months should be monitored. Due to the insuf-
ficient development of Sit P450 enzymes, while 0.15 
mg/kg dosage is used in older children, 0.1 mg/kg 
dosage is suitable for use in children below the age of 
six months. There are advantages and disadvantages 
of combinations made with the combination of a 
large number of drugs. A study was performed on the 
evaluation of postoperative 24 hours of vomiting in 
children aged 3-16 years. The patients were separated 
into two groups. The combination used in Group 1 
was determined as dexamethasone+ondansetron+-
placebo (153 patients and the combination for Group 
2 was determined as dexamethasone+ondansetron+-
droperidol (162 patients). A significant difference was 
not found between the two groups in terms of postop-
erative vomiting incidence (28% vs. 22%). Concern-
ing side effects, while numbness was seen in 10 pa-
tients with droperidol, it was only seen in two patients 
in the first group.[18]
Medication without Effect on PONV Prophylaxis
They are the use of nicotine patches for non-smokers, 
intraoperative O2 support, music therapy, cannabinoid 
(nabilone, tetrahydrocannabinol), isopropyl alcohol 
inhalation, intraoperative gastric decompression, PPI 
(esomeprazole) and ginger root application.
Conclusion
Since postoperative nausea and vomiting is a challeng-
ing process for patients and their relatives, preoperative 
risks and treatment strategies should be well determined 
and precautions should be taken with algorithms.
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